Stifel Nicolaus analyst Daniel Arias maintained a Hold rating on Qiagen (QGEN – Research Report) today and set a price target of $55.00. The company’s shares closed yesterday at $44.80.
According to TipRanks, Arias is an analyst with an average return of -8.4% and a 41.95% success rate. Arias covers the Healthcare sector, focusing on stocks such as Danaher, Illumina, and Mettler-Toledo.
In addition to Stifel Nicolaus, Qiagen also received a Hold from UBS’s John Sourbeer in a report issued today. However, on the same day, Berenberg Bank maintained a Buy rating on Qiagen (NYSE: QGEN).
See the top stocks recommended by analysts >>
QGEN market cap is currently $9.33B and has a P/E ratio of 30.13.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Qiagen (QGEN) Company Description:
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Read More on QGEN:
- QGEN Upcoming Earnings Report: What to Expect?
- Qiagen price target lowered to EUR 47 from EUR 48.45 at Morgan Stanley
- QIAGEN announces partnership with Penn State University to advance microbiome sciences
- Qiagen partners with Penn State to advance microbiome sciences
- Qiagen announces details for completion of share repurchase up to $300M
